SHENZHEN, China, May 10 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) announces that the company successfully acquired the first contract for its Freeze-dried Varicella Vaccine.
After the HTDS acquired Approval for its Freeze-dried MEVAC-vari in this Central American country (company's first Varicella vaccine approval in Latin America), the company closed the first contract in Guatemala and expects to ship and deliver its vaccine in May.
A source close to the company stated, "We are thrilled to close our first deal in less than two months after the final ministry approval. We offer very competitive products for the developing countries, and this is a great start for us on a market that offers a vast field of opportunities. Varicella, or chickenpox, is generally a mild viral illness. However, approximately 1 in 50 cases chickenpox associates with complications such as pneumonia and encephalitis, both attributed a high mortality rate. These complications can be fully eliminated by a simple vaccination. HTDS continues to seek out new opportunities in this part of the world as we are able to deliver affordable products to the parts of the world where basic health care lags behind only due to funding."
The company reminds its shareholders and followers to monitor PinkSheets.com Filing section and also our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/ for non newsworthy corporate updates.
For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link http://www.minamargroup.net/helpdesk. In this regard, Mina Mar Group works diligently to answer and address all the pressing issues regarding its clients to the shareholders' satisfaction. MMG is in constant contact with the companies, addressing, obtaining and processing all inquiries. MMG is often one of the advisors or IR companies utilized by the issuer. Depending on the location of the issuer and management's availability, it may take up to several days to address any pressing issues. In a normal course of business and a pending transaction the issuer may opt to remain silent in order not to lose advantage to a competitor. MMG is mindful that sometimes shareholders want answers now, which for above reasons cannot be fulfilled on a timely basis.
Don't be a victim. Report a stock basher to authorities. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit http://www.stockbasher.com/ and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and the remedies available to you as an individual investor. MMG encourages the readers to visit this investorshub.com blog and similar "investors" web sites with an open mind. Discover for yourself why and how USA based small businesses and the backbone of the economy suffer. Stay informed and do not allow entrepreneurs dreams, innovations, and their access to capital to be thwarted as "scalpers" and day traders vigorously day in and day out try to exploit and extinguish US innovation and progress for quick profits.
Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact email@example.com; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases